Regeneron Beats Investor Suit Over Medicare Drug Price Reporting
Bloomberg Law News · 2 hours ago
Regeneron Pharmaceuticals Inc. sidestepped investor allegations that it overhyped sales of its eye treatment through a practice of reimbursing credit card fees and leaving that out of price reports to federal healthcare regulators.
Continue reading at Bloomberg Law News →
Related Reading
- Gulfport program helps nursing home residents stay connected · WLOX · 12m ago
- Nuts and Bolts of Medicare and Medicaid 2026 · Foley Hoag · 36m ago
- Horizon Health hosting Medicare information sessions across the Wabash Valley · MyWabashValley.com · 44m ago
- Advocacy Submits Comments to CMS on Physician Fee Schedule Proposed Rule · Office of Advocacy (.gov) · 1h ago
- What is the difference between Medicare and Medicaid? · WPRI.com · 1h ago
- MatrixCare Speeds Up Post-Acute Strategy Under New CEO Jonathan Lujan · Home Health Care News · 2h ago